Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Inclusion Criteria:

* Must be able to provide informed consent
* In Dose-Escalation: Must have solid tumor malignancy or cutaneous T-cell lymphoma that has relapsed and is refractory to standard therapy, or for which no standard therapy exists
* In Expansion Phase: Must have melanoma or ovarian cancer that is histologically or cytologically confirmed
* Ovarian cancer patients must have recurrent of persistent non-mucinous disease, and must not have received more than 2 prior chemotherapeutic regimens
* Melanoma patients must have recurrent or persistent non-ocular AJCC Stage IIIC or IV disease that is surgically incurable and unresectable
* Melanoma patients with documented BRAF mutation that is known to be responsive to BRAF inhibitors must have failed or be intolerant to such inhibitors
* Must have measurable disease
* Must be able to provide access to archival (Dose-Escalation Phase) and/or fresh tumor tissue (Dose-Escalation and Expansion Phases) at Screening prior to study entry
* Must by at least 18 years old
* Must have adequate organ function

Exclusion Criteria:

* Prior cancer therapies must have completed at least 14 days or 5 half-lives (whichever is longer) prior to first dose of AMP-224
* Prior treatment with an anti-PD1 antibody therapy
* Known antibody response against prior antibody therapy or fusion protein therapeutics
* Major surgery within 4 weeks prior to first dose of AMP-224
* Prior allogeneic or autologous bone marrow or organ transplantation
* Known and/or a history or evidence of autoimmune disease except vitiligo, resolved childhood asthma and stable hypothyroidism
* Received an immunomodulatory drug within 2 weeks of first dose of AMP-224
* Active infections requiring antibiotics, physician monitoring, or recurrent fevers \>100.4 degrees fahrenheit associated with a clinical diagnosis of active infection
* Patients with cirrhosis
* Clinically significant cardiac or electrocardiogram abnormalities
* History or evidence of HIV
* Active viral disease (except when the viral infection is associated with the malignancy)
* Regular use of illicit drugs or a recent history of substance abuse
* Pregnant or breastfeeding women